Format

Send to

Choose Destination
Stat Med. 2007 Nov 30;26(27):4876-88.

Joint detection of important biomarkers and optimal dose-response model using penalties.

Author information

1
Global Statistics, Eli Lilly and Company, Mont-Saint-Guibert, Belgium. francois@clinbay.com

Abstract

We propose a method to jointly detect influential biomarkers and estimate how they change with dose. The assessment is made in dose-ranging trials collecting multiple outcomes for efficacy, safety, pharmacokinetics or pharmacodynamics. We regress all these outcomes versus a non-parametric transformation of the dose. The regression coefficients and the parameters from the dose-response model are simultaneously estimated using a penalized alternating least-squares method. We illustrate the technique with a phase I clinical trial and a metabonomic experiment in rats.

PMID:
17579922
DOI:
10.1002/sim.2960
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center